J Korean Diabetes.  2023 Dec;24(4):178-189. 10.4093/jkd.2023.24.4.178.

Position Statement on the Appropriateness and Significance of Adding the Glycated Hemoglobin Test to the National Health Examination

• Kim JH
• Kim DJ
• Kim J
• Park S
• Lee K
• Kang JG
• Ku EJ
• Kwon SK
• Kim WJ
• Lyu YS
• Son JW
• Eom YS
• Lee KA
• Lee J
• Lee JM
• Lee JH
• Jung JH
• Cho H
• Ju DL
• Choi D
• Kim CH
• Committee of the Health Insurance and Government Relation, Korean Diabetes Association

• KMID: 2550157
• DOI: http://doi.org/10.4093/jkd.2023.24.4.178

Abstract

The recent increase in the number of people with diabetes and the high incidence of complications carry a significant socioeconomic burden in addition to the disease burden and impact on personal health. Therefore, the Korean Diabetes Association and the Korean government have been making efforts to prevent the progression from pre-diabetes to diabetes through screening tests and to reduce diabetes complications and associated mortality in diabetic patients. Several studies in Korea have shown that glycated hemoglobin (HbA1c) provides complementary information to fasting plasma glucose (FPG) and improves clinical utility for diabetes screening. We hope that this consensus meeting will serve as an opportunity to identify additional diabetic patients who have not been diagnosed through a combination of FPG and HbA1c during a medical check-up. Our study is aimed to significantly reduce the lead time between diabetes onset and clinical diagnosis and initiation of diabetes treatment.

Keyword

Diabetes mellitus; Glycated hemoglobin; Mass screening

Reference

1.Korean Diabetes Association. Diabetes fact sheet in Korea. 2022. Available from: https://www.diabetes.or.kr/bbs/?code=fact_sheet&mode=view&num-ber=2499&page=1&code=fact_sheet (updated 2023 May 2).

2.Jung CH., Son JW., Kang S., Kim WJ., Kim HS., Kim HS, et al. Diabetes fact sheets in Korea, 2020: an appraisal of current status. Diabetes Metab J. 2021. 45:1–10.

3.Choi HH., Choi G., Yoon H., Ha KH., Kim DJ. Rising incidence of diabetes in young adults in South Korea: a national cohort study. Diabetes Metab J. 2022. 46:803–7.

4.Yang YS., Han K., Sohn TS., Kim NH. Young-onset type 2 diabetes in South Korea: a review of the current status and unmet need. Korean J Intern Med. 2021. 36:1049–58.

5.Kim YE., Park H., Jo MW., Oh IH., Go DS., Jung J, et al. Trends and patterns of burden of disease and injuries in Korea using disability-adjusted life years. J Korean Med Sci. 2019. 34(Suppl 1):e75.

6.Ha KH., Lee KA., Han KD., Moon MK., Kim DJ. Diabetes screening in South Korea: a new estimate of the number needed to screen to detect diabetes. Korean J Intern Med. 2023. 38:93–100.

7.Cowie CC., Rust KF., Byrd-Holt DD., Gregg EW., Ford ES., Geiss LS, et al. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006. Diabetes Care. 2010. 33:562–8.

8.Oh JY., Lim S., Kim DJ., Kim NH., Kim DJ., Moon SD, et al. A report on the diagnosis of intermediate hyperglycemia in Korea: a pooled analysis of four community-based cohort studies. Diabetes Res Clin Pract. 2008. 80:463–8.

9.Kim KS., Kim SK., Lee YK., Park SW., Cho YW. Diagnostic value of glycated haemoglobin HbA_1c for the early detection of diabetes in high-risk subjects. Diabet Med. 2008. 25:997–1000.

10.Qiao Q., Nakagami T., Tuomilehto J., Borch-Johnsen K., Balkau B., Iwamoto Y, et al. Comparison of the fasting and the 2-h glucose criteria for diabetes in different Asian cohorts. Diabetologia. 2000. 43:1470–5.

11.Lee JH., Chon S., Cha SA., Lim SY., Kim KR., Yun JS, et al. Impaired fasting glucose levels in overweight or obese subjects for screening of type 2 diabetes in Korea. Korean J Intern Med. 2021. 36:382–91.

12.Jeon JY., Ko SH., Kwon HS., Kim NH., Kim JH., Kim CS, et al. Prevalence of diabetes and pre-diabetes according to fasting plasma glucose and HbA1c. Diabetes Metab J. 2013. 37:349–57.

13.Hong S., Kang JG., Kim CS., Lee SJ., Lee CB., Ihm SH. Comparison of the clinical characteristics of diabetes mellitus diagnosed using fasting plasma glucose and haemoglobin A1c: The 2011 Korea National Health and Nutrition Examination Survey. Diabetes Res Clin Pract. 2016. 113:23–5.

14.Lim NK., Park SH., Choi SJ., Lee KS., Park HY. A risk score for predicting the incidence of type 2 diabetes in a middle-aged Korean cohort: the Korean genome and epidemiology study. Circ J. 2012. 76:1904–10.

15.Ikeda F., Doi Y., Ninomiya T., Hirakawa Y., Mukai N., Hata J, et al. Haemoglobin A1c even within non-diabetic level is a predictor of cardiovascular disease in a general Japanese population: the Hisayama Study. Cardiovasc Diabetol. 2013. 12:164.

16.Hilborne LH., Bi C., Radcliff J., Kroll MH., Kaufman HW. Contributions of glucose and hemoglobin A1c measurements in diabetes screening. Am J Clin Pathol. 2022. 157:1–4.

17.Korea National Institute of Health. Evaluation of the diabetes examination in the national screening program. Cheongju: Korea National Institute of Health;2022. Re-port No.: 11-1790387-000844-01. 97 p.

18.UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998. 352:854–65.

19.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998. 352:837–53.

20.Holman RR., Paul SK., Bethel MA., Matthews DR., Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008. 359:1577–89.

21.Jonas DE., Crotty K., Yun JDY., Middleton JC., Feltner C., Taylor-Phillips S, et al. Screening for pre-diabetes and type 2 diabetes: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2021. 326:744–60.

22.Gong Q., Zhang P., Wang J., Ma J., An Y., Chen Y, et al. Morbidity and mortality after lifestyle intervention for people with impaired glucose tolerance: 30-year results of the Da Qing Diabetes Prevention Outcome Study. Lancet Diabetes Endocrinol. 2019. 7:452–61.

23.CDC Diabetes Cost-Effectiveness Study Group. The cost-effectiveness of screening for type 2 diabetes. JAMA. 1998. 280:1757–63.

24.Herman WH., Ye W., Griffin SJ., Simmons RK., Davies MJ., Khunti K, et al. Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-De-tected Diabetes in Primary Care (ADDITION-Europe). Diabetes Care. 2015. 38:1449–55.

25.Rahman M., Simmons RK., Hennings SH., Wareham NJ., Griffin SJ. How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort. Diabetologia. 2012. 55:1651–9.

26.Harris MI., Klein R., Welborn TA., Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992. 15:815–9.

27.Porta M., Curletto G., Cipullo D., Rigault de la Longrais R., Trento M., Passera P, et al. Estimating the delay between onset and diagnosis of type 2 diabetes from the time course of retinopathy prevalence. Diabetes Care. 2014. 37:1668–74.

28.Thompson TJ., Engelgau MM., Hegazy M., Ali MA., Sous ES., Badran A, et al. The onset of NIDDM and its relationship to clinical diagnosis in Egyptian adults. Diabet Med. 1996. 13:337–40.

29.Chen TH., Yen MF., Tung TH. A computer simulation model for cost-effectiveness analysis of mass screening for Type 2 diabetes mellitus. Diabetes Res Clin Pract. 2001. 54(Suppl 1):S37–42.

30.Kahn R., Alperin P., Eddy D., Borch-Johnsen K., Buse J., Feigelman J, et al. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet. 2010. 375:1365–74.

31.Takahashi O., Farmer AJ., Shimbo T., Fukui T., Glasziou PP. A1C to detect diabetes in healthy adults: when should we recheck? Diabetes Care. 2010. 33:2016–7.

32.Ohde S., Moriwaki K., Takahashi O. Cost-effectiveness analysis for HbA1c test intervals to screen patients with type 2 diabetes based on risk stratification. BMC Endocr Disord. 2021. 21:105.

33.Gregg EW., Moin T. New USPSTF recommendations for screening for pre-diabetes and type 2 diabetes: an opportunity to create national momentum. JAMA. 2021. 326:701–3.

34.American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022. 45(Suppl 1):S17–38.

35.Ekoe JM., Goldenberg R., Katz P; Diabetes Canada Clinical Practice Guidelines Expert Committee. Screening for diabetes in adults. Can J Diabetes. 2018. 42(Suppl 1):S16–9.

36.Kim JH., Lim JS. Trends of diabetes and pre-diabetes prevalence among Korean adolescents from 2007 to 2018. J Korean Med Sci. 2021. 36:e112.

37.Hong YH., Chung IH., Han K., Chung S; Taskforce Team of the Obesity Fact Sheet of the Korean Society for the Study of Obesity. Prevalence of type 2 diabetes mellitus among Korean children, adolescents, and adults younger than 30 years: changes from 2002 to 2016. Diabetes Metab J. 2022. 46:297–306.

38.Mangione CM., Barry MJ., Nicholson WK., Cabana M., Chelmow D., US Preventive Services Task Force, et al. Screening for pre-diabetes and type 2 diabetes in children and adolescents: US Preventive Services Task Force recommendation statement. JAMA. 2022. 328:963–7.

39.Shah AS., Zeitler PS., Wong J., Pena AS., Wicklow B., Arslanian S, et al. ISPAD Clinical Practice Consensus Guidelines 2022: type 2 diabetes in children and adolescents. Pediatr Diabetes. 2022. 23:872–902.

40.ElSayed NA., Aleppo G., Aroda VR., Bannuru RR., Brown FM., Bruemmer D, et al. 2. Classification and diagnosis of diabetes: Standards of Care in Diabetes-2023. Diabetes Care. 2023. 46(Suppl 1):S19–40.

41.Nam HK., Cho WK., Kim JH., Rhie YJ., Chung S., Lee KH, et al. HbA1c cutoff for pre-diabetes and diabetes based on oral glucose tolerance test in obese children and adolescents. J Korean Med Sci. 2018. 33:e93.